PEGAVISION (6491) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 晶碩

PEGAVISION (6491) reported revenue of NT$793 million for Oct 2026, +13.0% year on year and +5.6% from the previous month. Revenue for Jan–Oct 2026 was NT$7.04 billion (+21.2% year on year).

Revenue for Oct 2026 was a record high (previous high: Nov 2023, NT$759.4 million). →

Year-on-year revenue growth: 17 months in a row. →

In Oct 2026, it ranked No. 6 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$596.6 million24/10Nov 2024 NT$578.2 millionDec 2024 NT$620 millionJan 2025 NT$502 millionFeb 2025 NT$525.3 million25/02Mar 2025 NT$566.2 millionApr 2025 NT$562.4 millionMay 2025 NT$523.9 millionJun 2025 NT$540.5 million25/06Jul 2025 NT$635 millionAug 2025 NT$631.2 millionSep 2025 NT$622.5 millionOct 2025 NT$701.6 million25/10Nov 2025 NT$603.9 millionDec 2025 NT$624.9 millionJan 2026 NT$659.5 millionFeb 2026 NT$556.9 million26/02Mar 2026 NT$669.2 millionApr 2026 NT$674.3 millionMay 2026 NT$716.2 millionJun 2026 NT$724 million26/06Jul 2026 NT$745.6 millionAug 2026 NT$750.4 millionSep 2026 NT$751 millionOct 2026 NT$793 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$793 million+13.0%+5.6%
Sep 2026NT$751 million+20.6%+0.1%
Aug 2026NT$750.4 million+18.9%+0.6%
Jul 2026NT$745.6 million+17.4%+3.0%
Jun 2026NT$724 million+33.9%+1.1%
May 2026NT$716.2 million+36.7%+6.2%
Apr 2026NT$674.3 million+19.9%+0.8%
Mar 2026NT$669.2 million+18.2%+20.2%
Feb 2026NT$556.9 million+6.0%-15.6%
Jan 2026NT$659.5 million+31.4%+5.5%
Dec 2025NT$624.9 million+0.8%+3.5%
Nov 2025NT$603.9 million+4.4%-13.9%
Oct 2025NT$701.6 million+17.6%+12.7%
Sep 2025NT$622.5 million+7.7%-1.4%
Aug 2025NT$631.2 million+11.1%-0.6%
Jul 2025NT$635 million+23.8%+17.5%
Jun 2025NT$540.5 million+6.2%+3.2%
May 2025NT$523.9 million-14.5%-6.9%
Apr 2025NT$562.4 million+8.9%-0.7%
Mar 2025NT$566.2 million-4.3%+7.8%
Feb 2025NT$525.3 million-7.2%+4.6%
Jan 2025NT$502 million-11.5%-19.0%
Dec 2024NT$620 million+9.1%+7.2%
Nov 2024NT$578.2 million-23.9%-3.1%
Oct 2024NT$596.6 million-16.0%+3.3%

Jan–Oct 2026 cumulative: NT$7.04 billion (+21.2% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: PEGAVISION vs PEC / PEGAVISION vs Lotus Pharm / PEGAVISION vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%
GKB1707NT$748.3 million-30.8%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16